Case Report

A rare case of isolated laryngotracheal amyloidosis with airway narrowing and vocal fold involvement

Mussanna Ahmed, MD
d*, Hamidreza Armani, BScb, Navid Salahi, MDa, Patrick Hammill, MDa

aDepartment of Radiology, SUNY Downstate Health Sciences University/Kings County Hospital, 451 Clarkson Ave, 3rd Fl, Rm B-3304, Brooklyn, NY 11203, USA
bSt. George’s University School of Medicine, True Blue, Grenada

ABSTRACT

Primary amyloidosis is a rare condition with 6-10 cases in a million, with focal involvement representing 9%-15% of those cases [1,2]. Isolated tracheobronchial amyloidosis is extremely rare and when present, can result in focal or diffuse thickening of the glottis, trachea and bronchi, leading to hoarseness, shortness of breath, and dysphonia. Computed tomography (CT) usually shows circumferential thickening of trachea and bronchi with or without calcifications and associated airway narrowing of affected segments. MRI demonstrates intermediate to low signal on T1, low signal on T2 and variable heterogeneous enhancement. Multiple conditions can result in thickening of the airway including but not limited to inflammatory, infectious, and neoplastic etiologies. Biopsy with histologic correlation provides a definitive diagnosis. Biopsied tissue demonstrates characteristic apple-green birefringence with Congo red stain. There is no cure for amyloidosis and the prognosis is quite variable depending on the extent of airway involvement. Current treatments are aimed at alleviating symptoms and include bronchoscopic debridement, laser therapy, and balloon dilation with adjuvant radiation therapy. Here, we present a rare case of a 47-year-old male with isolated laryngotracheal amyloidosis with marked airway narrowing and vocal fold involvement.

© 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Introduction

Amyloidosis represents a group of disorders characterized by the abnormal deposition of proteins in tissues. There are multiple types of amyloidosis which are broadly characterized as either primary or secondary. Primary amyloidosis or idiopathic amyloidosis is not associated with other diseases and is characterized by abnormal monoclonal light chain immunoglobulins production by plasma cells. Secondary amyloidosis usually occurs in the setting of chronic inflammatory disease or as a result of an immune response. Other types of amyloidosis include but are not limited to transthyretin amyloidosis which is inherited and caused by a mutation in the transthyretin gene and Beta-2 microglobulin amyloidosis.
which occurs in patients with chronic renal failure who are on dialysis.

Isolated tracheobronchial amyloidosis is a very rare condition characterized by submucosal deposition of AL amyloid which can result in progressive airway narrowing which patients presenting with nonspecific symptoms such as hoarseness, stridor and dysphonia. Prognosis is variable and dependent on the extent of airway involvement. Current therapies are aimed at preserving the airway, alleviating symptoms and minimizing recurrence.

Case report

A 47-year-old male presented with chronic progressive worsening shortness of breath on exertion, hoarseness, and dyspnea for several months. Upon admission, the vital signs were stable. Physical exam, basic lab work, and chest x-ray were unremarkable. The patient underwent a contrast-enhanced CT of the neck and chest, which revealed marked circumferential thickening and calcification of the larynx, trachea, and mainstem bronchi with supraglottic, glottic, and subglottic airway narrowing (Figs. 1 and 2). There is involvement of the vocal folds that is manifested as nodularity and calcification (Fig. 3). An extensive workup was conducted to rule out infectious and inflammatory etiologies including QuantiFERON, anti-DNA Ab, anti-nuclear Ab, cyclic citrullinated peptide Ab, Rheumatoid Factor, Hepatitis C Antibodies, and Hepatitis B core and surface antibodies, all of which were negative. Laryngoscopy revealed an inter-arytenoid scar with nodularity and limited abduction of true vocal folds, 60% subglottic region narrowing and thickening of the trachea and mainstem bronchi. A biopsy was performed to rule out malignancy, and subsequent pathologic analysis with Congo red staining and liquid chromatography with tandem mass spectrometry was compatible with primary AL-type lambda amyloidosis. Bone marrow biopsy ruled out any plasma cell neoplasm. Positron emission tomography did not show abnormal hypermetabolic activity. The patient was subsequently diagnosed with localized laryngotracheal amyloidosis arising from monoclonal plasma cells. The patient underwent laryngeal debridement, CO₂ laser therapy, and balloon dilation with adjuvant radiation therapy, which resulted in marked improvement of the patient’s symptoms. However, the patient required multiple follow-up balloon dilations due to disease recurrence.

Discussion

Primary amyloidosis is a very rare condition with 6-10 cases in a million in the United States. Focal disease involvement represents approximately 9%-15% of those cases [1,2]. Only 1% of primary amyloidosis involves isolated tracheobronchial involvement as seen in this case, with only a few hundred cases reported in the literature [3,4]. Most patients present in the fifth decade of life without definitive gender predilection [5].

Laryngotracheal amyloidosis involves submucosal deposition of AL amyloid and can cause focal or diffuse airway thickening, resulting in marked narrowing of the larynx, trachea,
and mainstem bronchi sometimes with vocal cord involve-
ment [2]. Patients commonly present with nonspecific symp-
toms such as hoarseness, shortness of breath on exertion, dys-
phonia and wheezing and as such, can be easily misdiagnosed
[6]. There are 3 patterns of amyloid airway involvement: prox-
imal, mid, and distal tracheobronchial disease. Patients with
the proximal pattern of disease usually present with upper
airway symptoms while patients with a mid or distal pattern
of involvement can present with lower respiratory symptoms
such as recurrent pneumonia or lobar collapse [7]. Differential
diagnostic considerations that also can result in diffuse
thickening of the upper airway must be considered and ex-
cluded including infiltrative neoplasms, sabre-sheath trachea
secondary to COPD, granulomatosis with polyangiitis, relaps-
ing polychondritis, sarcoidosis, tracheobronchial tubercul-
sis, tracheopathia osteochondroplastica, and extra-intestinal
manifestations of ulcerative colitis [8].

Imaging plays a vital role in the initial evaluation of dis-
ease and subsequent response to therapy. Plain film radiographs
are nonspecific and can appear normal. Occasionally
irregularity and nodularity can be seen in severe cases. CT is
the most commonly employed imaging modality and typically
demonstrates nodularity, symmetric focal, segmental or dif-
fuse thickening of the airway with resultant airway narrowing.
Calcification is frequently seen in longstanding cases. In-
volve ment of the vocal cords is very rare and when present
as on this case are seen as thickening and nodularity of
the glottic folds. When tracheal involvement is seen, the poste-
rior membrane is not spared (Fig. 4), which is in contradis-
tinction to cartilage diseases such as polychondritis or trac-
heobronchopathia osteochondroplastica [9]. Direct laryngo-
scopic or bronchoscopic evaluation is useful for assessment
of the vocal cords and glottis and to obtain tissue for biopsy.
18-Fluorodeoxyglucose positron emission tomography when
fused with CT may also play a role in early detection and mon-
itoring response to therapy; however, more robust investiga-
tion is required [10].

Pathologic analysis of biopsied tissue typically demon-
strates abnormally folded extracellular deposits of protein
with an affinity for Congo-red stain with characteristic yellow-
green birefringence under polarized light (Fig 5) [11]. Amyloi-
dosis can be systemic or localized. Systemic amyloidosis can
be further characterized as primary or secondary with pri-
mary amyloidosis being secondary to plasma cell dyscrasias
and secondary amyloidosis resulting from chronic inflamma-
tory/infectious conditions. Amyloidosis can also be classified
biochemically based on the composition of the fibrillar com-
ponent seen in the protein deposits. To date, over 2 dozen
subtypes have been identified with the majority of cases pre-
senting with deposition of amyloid light-chain (AL) and serum
amyloid A (AA) [12].

Current therapeutic options include bronchoscopic de-
bride ment, laser therapy, and balloon dilation. Disease recur-
rence has been reported and radiation therapy has shown decreased rates of recurrence [7,8]. Prognosis is generally poor in cases of airway amyloid and is largely determined by the extent of disease and degree of airway narrowing. Severe cases may require tracheostomy or laryngectomy for the preservation of the airway. Complicating factors include airway obstruction and rarely hemorrhage which can be fatal [13–15].

Conclusion

We presented a case of a 47-year-old male with isolated laryngotracheobronchial amyloidosis. This condition is very rare and can present with common nonspecific upper airway symptoms. Amyloidosis should be considered as a differential when patients present with hoarseness and shortness of breath, especially when other common conditions have been ruled out. We summarize the differential diagnostic considerations, characteristic imaging findings and current therapeutic options.

Patient consent

Informed consent was obtained from the patient prior to the publication of this article.

REFERENCES

[1] Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992;79(7):1817–22.
[2] Ma L, Bandarchi B, Sasaki C, Levine S, Choi Y. Primary localized laryngeal amyloidosis: report of 3 cases with long-term follow-up and review of the literature. Arch Pathol Lab Med 2005;129(2):215–18. doi:10.5858/2005-129-215-PLLARO.
[3] Piazza C, Cavaliere S, Foccoli F, Toninelli C, Bolzoni A, Peretti G. Endoscopic management of laryngo-tracheobronchial amyloidosis: a series of 32 patients. Eur Arch Otorhinolaryngol 2003;260(7):349–54. doi:10.1007/s00405-003-0592-0.
[4] Biwend ML, Menke DM, Calamia KT. The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature. Amyloid 2006;13(3):135–42. doi:10.1080/13506120600876773.
[5] Kourielis TV, Kyle RA, Dingli D, Buadi F, Kumar Shaji, et al. Presentation and outcomes of localized immunoglobulin light chain amyloidosis: the Mayo Clinic experience. Mayo Clin Proc 2017;92(6):908–17. doi:10.1016/j.mayocp.2017.02.016.
[6] Ding L, Li W, Wang K, Chen Y, Xu H, et al. Primary tracheobronchial amyloidosis in China: analysis of 64 cases and a review of literature. J Huazhong Univ Sci Technol Med Sci 2010;30(5):599–603. doi:10.1007/s11596-010-0549-7.
[7] O’Regan A, Fenlon HM, Beams IF Jr, Steele MP, Skinner M, Berk JL. Tracheobronchial amyloidosis. The Boston University experience from 1984 to 1999. Medicine (Baltimore) 2000;79(2):69–79. doi:10.1097/00005792-200003000-00001.
[8] Marom EM, Goodman PC, McAdams HP. Diffuse abnormalities of the trachea and main bronchi. AJR Am J Roentgenol 2001;176(3):713–17. doi:10.2214/ajr.176.3.760713.
[9] Crain MA, Lakhani DA, Balar AB, Hogg JP, Adelanwa A, Hailemiclai E. Tracheobronchial amyloidosis: a case report and review of literature. Radiol Case Rep 2021;16(9):2399–403. doi:10.1016/j.radcr.2021.05.082.
[10] Soussan M, Ouvrier MJ, Pop G, Galas JL, Neuman A, Weinmann P. Tracheobronchial FDG uptake in primary amyloidosis detected by PET/CT. Clin Nucl Med 2011;36(8):723–4.
[11] Picken MM. The pathology of amyloidosis in classification: a review. Acta Haematol 2020;143(4):322–34. doi:10.1159/000506696.
[12] Czeyda-Pommersheim F, Hwang M, Chen SS, Strollo D, Fuhrman G, Bhalla S. Amyloidosis: modern cross-sectional imaging. Radiographics 2015;35(5):1381–92. doi:10.1148/rg.2015140179.
[13] Mahmood S, Broidis F, Venner CP, Sachchithanantham S, Gilbertson J, Rowczenio D, et al. Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. Lancet Haematol 2015;2(6):e241–50. doi:10.1016/S2352-3026(15)00068-X.
[14] Paccalin M, Hachulla E, Cazalet C, Tricot L, Carreiro M, Rubi M, et al. Localized amyloidosis: a survey of 35 French cases. Amyloid 2005;12(4):239–45. doi:10.1080/13506120500351174.
[15] Mäkitie AA, Väli U, Kronlund H, Kääriäinen M, Pettersson T. Laryngeal amyloidosis as a cause of death. Amyloid 2013;20(1):58. doi:10.3109/13506129.2013.763785.